PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.
Peptides like GHK-Cu are discussed for hair regrowth, with mixed results; some users report no regrowth, while others notice thicker hair. Topical application is common, and proper sourcing and mixing are emphasized.
Isoflavones from soybeans may help limit estrogen's effects on the body, potentially preventing gyno. However, surgery is the only way to remove gland enlargement.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
The conversation discusses hair loss, genetics, and treatments like Dutasteride. It highlights the influence of genetics on hair loss, noting that indigenous people are less prone to it.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
The conversation is about evaluating the effectiveness and affordability of XHC Ginger Shampoo for hair loss. The user lists the ingredients and expresses that it looks promising and inexpensive.
The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.
GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.
The user is using a regimen of 0.5mg dutasteride, 5% minoxidil foam at night, hair gummies, and rosemary water in the morning to address hair loss. They are experiencing some regrowth and are advised to be patient, with suggestions to possibly increase minoxidil application to twice a day for better results.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.
Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.
Sons are offering free Biotin capsules, Thickening Clay, or Conditioner for hair care testing to UK men. Interested individuals can apply to receive these products without purchase.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.